{
    "eid": "2-s2.0-85137385802",
    "title": "Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer",
    "cover-date": "2022-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Asia",
        "HER2-positive metastatic breast cancer",
        "KAMILLA",
        "safety",
        "trastuzumab emtansine (TDM-1)"
    ],
    "authors": [
        "R. Wuerstlein",
        "P. Ellis",
        "F. Montemurro",
        "A. Ant\u00f3n Torres",
        "S. Delaloge",
        "Q. Zhang",
        "X. Wang",
        "S. Wang",
        "Z. Shao",
        "H. Li",
        "A. Rachman",
        "M. Vongsaisuwon",
        "H. Liu",
        "S. Fear",
        "C. Pe\u00f1a-Murillo",
        "C. Barrios"
    ],
    "citedby-count": 3,
    "ref-count": 32,
    "ref-list": [
        "Kadcyla\u00ae prescribing information: Genentech, Inc",
        "Kadcyla\u00ae summary of product characteristics",
        "Trastuzumab emtansine: mechanisms of action and drug resistance",
        "Trastuzumab emtansine for HER2-positive advanced breast cancer",
        "Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label, phase 3 trial",
        "Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial",
        "A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience",
        "T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study",
        "Efficacy and safety of trastuzumab emtansine in HER2 positive metastatic breast cancer: real-world experience",
        "Real-world data on T-DM1 efficacy \u2013 results of a single-center retrospective study of HER2-positive breast cancer patients",
        "Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1",
        "Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis",
        "Common Terminology Criteria for Adverse Events (CTCAE), v4.0",
        "Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase III EMILIA study",
        "Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine",
        "Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer",
        "Trastuzumab deruxtecan in previously treated HER2-positive breast cancer",
        "Trastuzumab emtansine for residual invasive HER2-positive breast cancer",
        "Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study",
        "Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial",
        "5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)",
        "AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021",
        "Tykerb\u00ae prescribing information: Novartis Pharmaceuticals Corporation",
        "Nerlynx\u00ae prescribing information: Puma Biotechology, Inc",
        "TukysaTMprescribing information: Seattle Genetics, Inc",
        "Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u22652 HER2-directed regimens: phase III NALA trial",
        "Tucatinib, trastuzumab, and caepcitabine for HER2-positive metastatic breast cancer",
        "Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial",
        "Pyrotinib: first global approval",
        "Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and /or trastuzumab: a randomized/phase II study",
        "Enhertu\u00ae prescribing information: Daiichi Sankyo, Inc"
    ],
    "affiliation": [
        {
            "affiliation-city": "Shanghai",
            "@id": "60108904",
            "affilname": "Fudan University Shanghai Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60073540",
            "affilname": "Zhejiang Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073540",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Candiolo",
            "@id": "60070526",
            "affilname": "Candiolo Cancer Institute-FPO- IRCCS",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070526",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Villejuif",
            "@id": "60027386",
            "affilname": "Institut de Cancerologie Gustave Roussy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027386",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Zaragoza",
            "@id": "60022336",
            "affilname": "Hospital Miguel Servet",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022336",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Harbin",
            "@id": "60021615",
            "affilname": "Harbin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021615",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Porto Alegre",
            "@id": "60015760",
            "affilname": "Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015760",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "London",
            "@id": "60009797",
            "affilname": "Guy's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009797",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60008510",
            "affilname": "Beijing Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008510",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60008201",
            "affilname": "F. Hoffmann-La Roche AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Munich",
            "@id": "60000291",
            "affilname": "Klinikum der Universit\u00e4t M\u00fcnchen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000291",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Jakarta",
            "@id": "114030941",
            "affilname": "MRCCC Siloam Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/114030941",
            "affiliation-country": "Indonesia"
        }
    ],
    "funding": [
        "F. Hoffmann-La Roche"
    ]
}